LONDON--(BUSINESS WIRE)--With FDA guidelines likely to become more stringent under the Obama administration, Pharma oncology companies are meeting to look at how to develop and execute a Risk Evaluation and Mitigation Strategy (REMS).
LONDON--(BUSINESS WIRE)--With FDA guidelines likely to become more stringent under the Obama administration, Pharma oncology companies are meeting to look at how to develop and execute a Risk Evaluation and Mitigation Strategy (REMS).
